2001year

Borui Pharmaceutical was established

2006year

Developed Entecavir synthetic process with independent property rights

2010year

Established a wholly-owned subsidiary, Xintai Pharmaceutical

2012year

Founder Dr. Yuan Jiandong selected into the "Thousand Talents Program"

2013year

Xintai Pharmaceutical, a wholly-owned subsidiary, was completed and put into operation, and Borui became a pharmaceutical group of the entire industry chain;
Passed cGMP certification of FDA for the first time

2015year

Completed the shareholding system transformation and renamed Borui Biomedical (Suzhou) Co., Ltd .;
Xintai Pharmaceutical and Borui Taixing both passed the new domestic GMP certification

2016year

Passed the cGMP inspection of EU EMDA for the first time;
Passed FDA cGMP certification again

2017year

"Zero defect" passed the US FDA inspection;
Caspofungin injection is marketed in Europe;
Passed KFDA official certification for the first time;
Passed Japan PMDA official certification for the first time

2019year

Science and technology board listed
First US ANDA approved